Conversion to sirolimus for chronic renal allograft dysfunction: risk factors for graft loss and severe side effects

Daniel Abramowicz, Karine Hadaya, Marc Hazzan, Nilufer Broeders, Anh-Dung Hoang, Lidia Ghisdal, Christian Noel and Karl Martin Wissing

Service de Néphrologie, Hopital Erasme, Bruxelles, Belgique and Service de Néphrologie, Hopital Calmette, Lille, France

Abstract

We retrospectively reviewed our experience with 45 kidney transplant recipients (KTR) that were switched from CNI to SRL, mainly for chronic allograft dysfunction (CAD) (41/45). The mean serum creatinine at switch was 2.5 ± 0.8 mg/dl. At 1 year, patient survival was 93%. Death-censored graft survival was 67% at 1 year and 54% at 2 years. SRL was stopped because of severe side effects in 15 patients. Among these, eight patients developed ‘de novo’ high-grade proteinuria. Univariate analysis revealed that (1) a higher SRL level at 1 month was a predictor of SRL withdrawal due to severe side effects (P = 0.006), and (2) predictors of graft failure after SRL conversion were low SRL loading dose (P = 0.03) and a higher creatinine level at conversion (P = 0.003).

In conclusion, the therapeutic index of SRL in patients suffering from CAD is narrow, with high exposure triggering serious adverse events that may mandate SRL discontinuation, while too low exposure may expose patients to under-immunosuppression and graft loss.

Keywords: graft survival; proteinuria; renal transplantation; sirolimus; toxicity

Introduction

In some renal transplant recipients, CsA or tacrolimus may lead to the development of CAD. SRL, a potent immunosuppressant with a distinct mechanism of action, may help to prevent CAD progression [1–9]. However, having observed a high rate of SRL discontinuation in patients switched from CNI- to SRL-based immunosuppression, we retrospectively analysed our data to further elucidate the safety, efficacy and side effects of this CAD-attenuating strategy.

Patients and methods

Our data include 45 renal transplant recipients from two centres who were switched from CNI- to SRL-based immunosuppressant therapy. The CNI was abruptly discontinued and patients were switched to SRL+steroids. Thirty-nine patients also received an anti-metabolite (24 received MMF; 5 received AZA).

Mean age at switch was 42.3 ± 11 (SD) years, and 22 patients (49%) were male. PRA was below 30% in 35/44 patients (79.5%), with a mean number of HLA mismatches of 3.1 ± 1.1. Twenty-four percent had experienced previous acute rejection before switching to SRL. The median time from transplantation to conversion was 28.1 months (range, 1.4–167 m), and the mean serum creatinine at the time of switch was 2.5 ± 0.8 mg/dl. There was no deterioration of renal graft function during the 3-month preceding conversion (serum creatinine at −3 months: 2.46 ± 1.24; at −1 month: 2.46 ± 0.85, P = NS).

For 23 patients, the mean (±SD) SRL loading dose was 12.00 ± 4.41 mg/day for 3 consecutive days, with target trough levels ranging from 10 to 30 ng/ml. In the remaining patients, the SRL loading dose was 0.1 mg/kg for 3 days (mean dose: 5.05 ± 1.68 mg) and the target trough level was 10 ng/ml. Median follow-up (death, graft loss or last FU) after SRL conversion was 8.6 months (range, 0.8–37 months). Proteinuria was evaluated either by the morning protein/creatinine ratio or by dipstick analysis.

Results

Patient survival, graft survival and SRL discontinuation

Three deaths occurred after SRL switch. One patient died from multiple organ failure on Day 58, one from sudden death on Day 96 and one from cerebral haemorrhage on Day 156. Actuarial patient survival was 93% at 1 year. Twelve patients experienced loss of graft function and resumed chronic haemodialysis at a median of 107 days after SRL conversion (range, 23–523). Death-censored graft survival was 67% at 1 year and 54% at 2 years (Figure 1a). In addition, SRL was discontinued in 15 patients (33.3%)...
because of the occurrence of severe side effects (some patients developed more than one side effect): resistant anaemia, N = 1; multiple abdominal abscesses following acute pancreatitis, N = 1; hepatitis, N = 1; peritransplant abscess, N = 1; delayed wound healing, N = 1; stroke, N = 1; infra-therapeutic SRL levels leading to AR, N = 1; raised \( \text{Screat} > 25\% \), N = 1; severe acneiform cutaneous lesions, N = 2; severe hyperlipaemia, N = 2; and de novo high-grade proteinuria, N = 8 (17.7%). In summary, SRL was stopped in 30/45 (66.6%) patients after conversion (3 deaths, 12 graft loss and 15 discontinuation for side effects). The actuarial proportion of patients remaining on SRL therapy over time was 33.6% at 1 year and 26.9% at 2 years after conversion (Figure 1b).

Univariate analysis revealed that SRL levels were higher at 1 month when the 15 AE-experiencing, SRL-discontinuing patients were compared with the 30 SRL-continuing patients (19.4 ± 10 ng/ml versus 11.7 ± 7.8 ng/ml, respectively, \( P = 0.006 \)).

**De novo heavy proteinuria**

The mean proteinuria of the whole cohort was 1.0 g/day at conversion, 1.7 g/day at 1 month (\( P = 0.008 \)) and 1.9 g/day at 3 months (\( P < 0.0001 \)). Eight out of 45 patients (18%) developed heavy proteinuria (mean 4.4 g/day, range, 2.5–9.8), which was detected at a median of 9.5 days after conversion (range, 5–127). Their baseline proteinuria was 1.24 ± 1.16 g/day. Proteinuria returned to pre-switch levels after SRL discontinuation in 7/8 patients.

**Graft function and risk factors for graft loss after SRL switch**

Serum creatinine levels of the cohort are shown in Figure 2. For the overall cohort, serum creatinine levels were stable during the 3 months before conversion, but increased significantly thereafter. When the subgroup of patients who did not return to dialysis was analysed separately, conversion to sirolimus had no detectable effect on graft function (mean \( \text{Pcreat} \): 2.3 ± 0.7 at conversion versus 2.2 ± 0.8 at final analysis; \( P = \text{NS} \); Figure 2). Univariate analysis comparing the 12 patients who lost their graft with the 33 patients who retained a functioning graft revealed that a lower SRL loading dose (5.2 mg/day versus 9.8 mg/day, \( P = 0.03 \)) and higher serum creatinine at the time of switch (3.10 mg/dl versus 2.27 mg/dl, \( P = 0.003 \)) were significant risk factors for subsequent graft loss. Proteinuria at switch was higher in patients who went on to lose their graft but this did not reach statistical significance (1.46 g/day versus 0.84 g/day, \( P = 0.29 \)).

**Discussion**

We must first acknowledge that the three obvious shortcomings to our study are that it is retrospective, it has no control group and it involves difficult-to-manage CAD patients. Notwithstanding, a high incidence of severe side effects mandating SRL discontinuation was observed in one-third of the patients and was typical of those seen with mTOR inhibitors.

In our cohort, we could identify that high SRL trough levels at 1 month after the switch was a significant risk factor for severe side effects. In our early experience, we targeted SRL trough levels between 20 and 30 ng/ml, as recommended in the two Phase II trials where de novo KTR received CNI-free, SRL-based therapy [10,11]. Nowadays, lower trough levels, such as 8–15 ng/ml, are targeted, with less toxicity [12].

We found no improvement of renal function after the switch to sirolimus. This contrasts with a recent meta-analysis, where patients with CAD switched from CNI to SRL experienced a significant 6 ml/min improvement in creatinine clearance [13]. This difference is probably due to the patients in the meta-analysis having better preserved renal function at the time of switch (\( \text{CrCl} \) was 47 ml/min, versus 35 ml/min in our study). Indeed, results from the recent ‘Convert’ study, where patients with creatinine clearance <40 ml/min experienced a high incidence of adverse events with no corresponding renal function benefits [14], have suggested that conversion to SRL following
CAD should only be undertaken in patients with creatinine <2.5 mg/dl [15]. Similarly, Wali et al. concluded that conversion from tacrolimus to SRL is ineffective when the mean creatinine level reaches 3.8 mg/dl [16]. Our findings substantiate these observations.

Conflict of interest statement. None declared.

References

1. Dominguez J, Mahalati K, Kiberd B et al. Conversion to rapamycin immunosuppression in renal transplant recipients: report of an initial experience. Transplantation 2000; 70: 1244
2. Diekmann F, Waiser J, Fritsche L et al. Conversion to rapamycin in renal allograft recipients with biopsy-proven calcineurin inhibitor-induced nephrotoxicity. Transplant Proc 2001; 33: 3234
3. Cotterell AH, Fisher RA, King AL et al. Calcineurin inhibitor-induced chronic nephrotoxicity in liver transplant patients is reversible using rapamycin as the primary immunosuppressive agent. Clin Transplant 2002; 16: 49
4. Morelon E, Kreis H. Sirolimus therapy without calcineurin inhibitors: Neckher hospital 8-year experience. Transplant Proc 2003; 35: 52S
5. Fairbanks KD, Eustace JA, Fine D et al. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus. Liver Transpl 2003; 9: 1079
6. Egidi MF, Cowan PA, Naseer A et al. Conversion to sirolimus in solid organ transplantation: a single-center experience. Transplant Proc 2003; 35: 131S
7. Diekmann F, Budde K, Oppenheimer F et al. Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant 2004; 4: 1869
8. Bumbea V, Kamar N, Riba D et al. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. Nephrol Dial Transplant 2005; 20: 2517
9. Stallone G, Infante B, Schena A et al. Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients. J Am Soc Nephrol 2005; 16: 3755
10. Groth CG, Backman L, Morales JM et al. Sirolimus European Renal Transplant Study Group. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Transplantation 1999; 67: 1036
11. Kreis H, Cisterne JM, Land W et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000; 69: 1252
12. Diekmann F, Gutierrez-Dalmau A, Torregrosa JV et al. Sirolimus monotherapy: feasible immunosuppression for long-term follow-up of kidney transplantation—a pilot experience. Transplantation 2005; 80: 1344
13. Mulay AV, Cockfield S, Stryker R et al. Conversion from calcineurin inhibitors to sirolimus for chronic renal allograft dysfunction: a systematic review of the evidence. Transplantation 2006; 82: 1153
14. Schena FP, Wali RK, Pascoe MD et al. A randomized, open label, comparative evaluation of the safety and efficacy of conversion from calcineurin inhibitors to sirolimus versus continued use of calcineurin inhibitors in renal allograft recipients [Abstract]. Transpl Int 2005; 18(Suppl 1): 155
15. Diekmann F, Campistol JM. Conversion from calcineurin inhibitors to sirolimus in chronic allograft nephropathy: benefits and risks. Nephrol Dial Transplant 2006; 21: 562
16. Wali RK, Mohanlal V, Ramos E et al. Early withdrawal of calcineurin inhibitors and rescue immunosuppression with sirolimus-based therapy in renal transplant recipients with moderate to severe renal dysfunction. Am J Transplant 2007; 7: 1572

Received for publication: 30.7.07
Accepted in revised form: 21.5.08